<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-4QYZT2RS/52787496-e36a-4697-bdfb-17ed7a9d1b71/PDF"><dcterms:extent>335 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-4QYZT2RS/a3cecc26-d829-4af9-94d9-45f413304542/TEXT"><dcterms:extent>0 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2010-2025"><edm:begin xml:lang="en">2010</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-4QYZT2RS"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-UQS2GZJE" /><dcterms:issued>2022</dcterms:issued><dc:creator>Čamernik, Maja</dc:creator><dc:creator>Fujs, Nada</dc:creator><dc:creator>Herček, Tea</dc:creator><dc:creator>Kolar, Matej</dc:creator><dc:creator>Kozmus, Nika</dc:creator><dc:creator>Pance, Slobodanka</dc:creator><dc:creator>Pavlović, Dragana</dc:creator><dc:creator>Rehar, Mateja</dc:creator><dc:creator>Rožič, Branka</dc:creator><dc:creator>Skubic, Janja</dc:creator><dc:creator>Sladojević, Bojan</dc:creator><dc:creator>Šumljak, Urška</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:29</dc:format><dc:format xml:lang="sl">str. 99-105</dc:format><dc:identifier>DOI:10.38031/slovpediatr-2022-2-07</dc:identifier><dc:identifier>COBISSID:111642371</dc:identifier><dc:identifier>ISSN:1318-4423</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-4QYZT2RS</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Združenje pediatrov Slovenije</dc:publisher><dc:publisher xml:lang="sl">Združenje specialistov šolske in visokošolske medicine Slovenije</dc:publisher><dcterms:isPartOf xml:lang="sl">Slovenska pediatrija</dcterms:isPartOf><dc:subject xml:lang="sl">COVID-19</dc:subject><dc:subject xml:lang="sl">otroci</dc:subject><dc:subject xml:lang="sl">pandemija</dc:subject><dc:subject xml:lang="sl">pediatrija</dc:subject><dc:subject xml:lang="sl">SARS-CoV-2</dc:subject><dcterms:temporal rdf:resource="2010-2025" /><dc:title xml:lang="sl">Covid-19 v pediatriji in naše izkušnje| Covid-19 in pediatrics and our experiences|</dc:title><dc:description xml:lang="sl">Introduction: The purpose of the research was to analyze the treatment of children during the SARS CoV-2 epidemic in the red zone of of the Pediatric Clinic in Ljubljana. Methods: A quantitative, non-experimental type of research was used. All hospitalized children from October to March 2022 were included. Data were obtained using the Clinical information system. Results: 203 children, (113 (55.7%) boys and 90 (44.3%) girls) were included. The majority were aged 6–12 years 58 (26.1%). Most SARS-CoV-2 positive children (93,6%) were hospitalized in the red zone of Admission and Triage Department red zone and 10 (6.4%) in the another departments. The majority were hematological oncology patients (22.7%), and the leastowest number of children was in the field of allergology, rheumatology and clinical immunology 3%. Thirty-nine (19.2%) children received Sotrovimab, 24 (11.8%) Regen-cov and Remdesevir 12 (5.90%). Discusion: During the SARS-CoV-2 epidemic, work at the Pediatric Clinic has fully adapted to ensure safe management of children despite the reduced scope of work. Treatment of children with cancer, newborns, and other children with serious acute or chronically ill children from all over Slovenia were treated without interruption in the red zone of the Pediatric clinic in Ljubljana</dc:description><dc:description xml:lang="sl">Metode: Uporabili smo kvantitativno, neeksperimentalno metodo raziskave. Vključili smo vse hospitalizirane otroke od oktobra do marca 2022. Podatke smo pridobili iz informacijskega sistema Clinical. rezultati: Analizirali smo 203 otroke (113 (55,7 %) fantov in 90 (44,3 %) deklet). Največ je bilo šolskih otrok 58 (26,1 %), starih 6–12 let. Večina SARS-Cov-2 pozitivnih otrok (93,6 %) je bila sprejeta v rdečo cono, 10 (6,4 %) pa na druge oddelke v kliniki. Največ je bilo hematoonkoloških bolnikov (22,7 %), najmanj pa otrok z boleznimi s področja alergologije, revmatologije in klinične imunologije (3 %). Sotrovimab je prejelo 39 otrok (19,20 %), Regencov 24 (11,8 %) in Remdesevir 12 (5,90 %) otrok. Zaključek: Med epidemijo SARS-CoV-2 smo na Pediatrični kliniki delo v celoti prilagodili, da bi bolnim otrokom zagotovili varno obravnavo tudi ob omejenem obsegu dela. V rdeči coni Pediatrične klinike je nemoteno potekalo zdravljenje otrok z rakom, novorojenčkov ter drugih težje kronično ali akutno bolnih otrok iz vse Slovenije z okužbo s SARS-Cov-2</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-4QYZT2RS"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-4QYZT2RS" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-4QYZT2RS/52787496-e36a-4697-bdfb-17ed7a9d1b71/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo za pomoč otrokom s presnovnimi motnjami</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-4QYZT2RS/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-4QYZT2RS" /></ore:Aggregation></rdf:RDF>